Organic Active Ingredients TRIZ Cases

Separate active, sweetener, and flavor particles address bitter taste and delayed release in oral powder delivery while improving mouthfeel.

Reboxetine targets cataplexy, daytime sleepiness, concentration, and inadvertent naps through selective norepinephrine inhibition.

Heterocyclic pyrazoles address inadequate type III RTK therapies by inhibiting wildtype and mutant FLT3, PDGFR, c-KIT, and CSF-1R.

Crosslinked MHA hydrogel encapsulates hormone in a dual-chamber syringe, enabling sustained delivery and more consistent dosing.

Age-restricted ENDS devices can block unauthorized use through a security tag that handles identity or age verification.

Precursor-directed biosynthesis and C11 alcohol modification address verticillin’s limited supply and poor solubility while preserving anticancer potency.

Modified oligonucleotides hybridize with KCNT1 RNA to reduce channel activity and address seizures in pharmaco-resistant epilepsies.

Pseudo-irreversible HSD-1 inhibitors form an NADPH-bound complex to lower intracellular cortisol and address tissue-specific morbidity.

Selective M4 allosteric compounds augment receptor activity through a distinct binding site, potentially limiting peripheral side effects.

A lipid pre-formulation creates a liquid crystalline phase in aqueous fluid to sustain prostacyclin release and reduce injection-site irritation.

For non-dialysis CKD anemia, daprodustat raises hemoglobin while delivering clinically relevant fatigue and vitality improvements.

Copper-catalyzed click chemistry links azido targeting ligands to propargyl nucleic acids for flexible PSMA-targeted RNAi delivery.

GalNAc clusters improve gapmer potency and half-life in humans, enabling lower drug amounts and weekly, monthly, or quarterly dosing.

Low-purity oily sonrotoclax intermediate is converted to a stable oxalate solid for scalable production.

APOL1 inhibitors target the disease mechanism behind high-risk genotypes, supporting treatment of chronic kidney disease and diabetic retinopathy.

Short-lived proteases can compromise clotting; lipid nanoparticles deliver siRNA for sustained, controlled fibrinogen reduction.

Allele-specific siRNAs target PNPLA3 mRNA to reduce hepatic triglyceride accumulation and inflammation in NAFLD and related liver disease.

Novel LCMT-1 compounds aim to bypass kinase-related drug resistance by altering PP2A methylation and sensitizing cancer cells to radiation.

Pacritinib targets FLT3 mutations in AML, addressing drug resistance and toxicity concerns linked to earlier multikinase inhibitors.

RE104 HCl prodrug injections address solubility and pharmacokinetic uncertainty while targeting shorter psychedelic experiences.

Modified 19-nor steroids tune GABA receptor chloride conductance to address inconsistent dose response and side effects in CNS treatments.

A separated dosage form releases tegoprazan immediately and NSAIDs in a controlled manner to reduce gastrointestinal side effects while preserving treatment.

Carbonyl-protected intermediates and an SNAr step address low yield and instability, enabling Sonrotoclax synthesis above 70% yield and 90% purity.

Bisphosphonate lipid LNPs bind bone minerals to localize RNA therapeutics, improving delivery to bone and marrow cells while limiting toxicity.

Substituent-tuned gamma-carbolines combine 5-HT2A, dopamine, and mu-opioid activity for potential OCD and OUD treatment.

Engineered CDRs give anti-LY6H antibodies high-affinity binding and enable targeted killing of LY6H-expressing cells.

Calcium ions and cationic lipids support nucleic acid encapsulation and endosomal escape while maintaining controlled particle size for delivery.

BCL6 ligand-directed degraders recruit E3 ligases to trigger ubiquitination and proteasome-mediated removal of the target protein.

Variable R1–R8 substituents tune benzofuran TRPM3 antagonists toward potency with fewer side effects for pain and epilepsy.

Formula-based ionizable lipids help nanoparticles deliver therapeutics beyond the liver to endothelial, mesenchymal, and cancer cells.

Patient-reported outcome questionnaires track dysphagia before and during EoE treatment, while eosinophil counts help assess response.

Specific polyphenols, amino acids, nucleotides, and inulins help mask tectorigenins’ taste and reduce decomposition in oral anti-obesity compositions.

Different-molecular-weight PLGA microparticles encapsulate Tacrolimus for linear release lasting up to two months without an initial burst.

Partial visual-cycle inhibition reduces cytotoxic bisretinoid formation while maintaining sufficient activity to help preserve photoreceptor function.

Follistatin-binding antibodies and small molecules target insulin resistance by reducing follistatin activity and improving insulin sensitivity.

Targeting BTK-C palmitoylation at residues 13 and 16 can block cancer-cell signaling and proliferation while preserving normal immune function.

Crosslinked MHA microbeads address inconsistent hormone dosing by releasing encapsulated hormone steadily in subcutaneous tissue.

A dual-chamber syringe mixes diluent with crosslinked MHA hydrogel to support subcutaneous hormone release and improved absorption.

Water-soluble succinic acid struggles to enter cells; tumor cell-derived microparticles provide targeted delivery with higher loading capacity.

Bifunctional PROTACs recruit E3 ubiquitin ligases to degrade estrogen receptors, addressing tamoxifen’s partial agonism.

Current Alzheimer’s treatments may relieve symptoms without improving cognition; NMDA receptor modulation targets cognitive decline through a disease-focused approach.

Limited treatment options are addressed with small-molecule Formula I inhibitors of plasma kallikrein for angioedema and retinal disorders.

Tranilast formulations target new amyloid fibril formation while promoting dissolution or elimination of existing deposits in vivo.

Negatively charged and bulky oligonucleotides struggle to cross cell membranes; peptide–lipid nanoparticles bind, enter, and release them inside cells.

A wax-matrix, enteric-coated formulation releases 25-hydroxyvitamin D2/D3 in the ileum to maintain stable blood levels.

Immune-suppressive cancers can resist single agents; combining selective HDAC3 inhibition with checkpoint blockade raises MHC class II expression.

Antibody targeting concentrates glucocorticoid receptor agonists at antigen-bearing cells, limiting systemic exposure and side effects.

Adding oxygen to the central ring creates tetrahydropyranopyrazoles with greater metabolic stability and lower CYP inhibition.

Poor solubility and stability limit oral delivery of a CK1α molecular glue degrader; polymer solid dispersions increase exposure.

Controlled pH and excipients help keep high-concentration soluble insulin stable, maintaining predictable release and a U200-like profile.

This case forms lipid nanoparticles in acidic buffer, then adds nucleic acid to simplify encapsulation without lyophilization.

This case uses 7-KLCA and its conjugates to restore gut microbiome balance by promoting beneficial bacteria and inhibiting harmful strains.

Heteroaryl TACC inhibitor compounds improve oral stability and reduce working doses, with tumor growth inhibition in xenograft models.

This case uses antibodies that bind NGF and block its activity to address osteoarthritis pain and inflammation with less frequent dosing.

This composition uses botanical extracts to boost endogenous GLP-1 signaling while avoiding synthetic GLP-1RA side effects.

This case combines oleic or isostearic acid with cationic lipids to improve transmucosal and gastrointestinal drug absorption.

This case uses Formula 1 compounds to raise Klotho expression and protect retinal pigment epithelial cells from oxidative stress.

Developing specific crystalline polymorphs of 8-bromo-pyrido-pyrimidine hydrochloride resolves poor stability in high temperature and humid environments.

Compounds with specific chemical structures inhibit PDE9A to improve cognitive function in Alzheimer's disease.

Chi3l1 siRNA suppresses Twist1 expression and activates Th1 responses to inhibit lung metastasis without inducing apoptosis.

Pyrazine derivatives target aberrant FGFR pathways to overcome tumor resistance in cancer therapies.

Amphiphilic kanamycin derivatives inhibit connexin hemichannels via O-position substitutions, reducing antimicrobial side effects while maintaining efficacy.

Dual-release hydrocortisone formulation mimics natural circadian cortisol rhythm, reducing side-effects from unphysiological plasma profiles.

Selective ITK inhibitors decrease melanoma cell proliferation and migration, overcoming resistance to current therapies.

Topical compositions combining hyaluronic acid and iota-carrageenan inhibit viral adherence to cell membranes.

Transscleral injection delivers gene therapies to the suprachoroidal space for targeted ocular treatment.

Iodinated heterocyclic compounds boost fluorescence brightness and photostability, resolving insufficient signal detection in biological autoluminescence.

Fibrin-specific nanogels deliver fibrinolytic agents directly to occlusions via targeted binding.

Dual partial agonists bind selectively to serotonin 5-HT7 and 5-HT1A receptors with high affinity.

Acidified non-aqueous solvents stabilize labile covalent bonds in histone deacetylase inhibitors, preventing hydrolysis and extending shelf life.

A segmented food composition uses plant extracts to enhance metabolic functions and support weight reduction.

Omeprazole paste achieves three-year stability without thickening agents, reducing production costs and improving safety through synergistic formulation.

Adenine compounds modulate PINK1 kinase activity to treat neurodegenerative and mitochondrial disorders.

Tricyclic thiadiazine dioxide compounds inhibit BACE enzymes, reducing amyloid-beta production and addressing underlying Alzheimer's disease causes.

Administering cannabinoid receptor agonists before radiation therapy increases cell kill percentages beyond additive effects.

A single-layer matrix tablet uses hydroxypropylmethyl cellulose and carbomer to achieve controlled ropinirole release.

Adjusting molecular weight to 100-1000 kDa reduces viscosity, enabling sterile filtration of glycated chitosan while maintaining immunoadjuvant efficacy.

Converting the free base to a tosylate salt resolves poor solubility and bioavailability, enabling effective oral administration and storage stability.

Administering isolated LEMD3 polypeptides antagonizes TGF-beta-driven Smad2/3 transcription, addressing underlying pathology in pulmonary fibrosis.

Adamantane derivatives shift follicles from telogen to anagen phase while reducing sebum secretion for effective alopecia treatment.

Segmented pocket holds cannabinoid carrier against absorbent tampon matrix to prevent dissolution interference during insertion.

A synthetic oligosaccharide formulation uses lipophilic and hydrophilic surfactants to create a stable microemulsion for oral delivery.

Pyridoindole derivatives modify molecular structures to balance high potency with improved tolerance, addressing limitations of existing CK2 inhibitors.

Reversible FXIIa inhibitors avoid covalent binding to reduce off-target effects and cytotoxicity while maintaining therapeutic efficacy.

Low molecular weight heterocyclic compounds suppress cytotoxic peptide formation to overcome insufficient inhibitor potency.

A small molecule compound selectively inhibits SRSF6 protein to reduce abnormal alternative splicing events in cancer cells.

Branched poly(beta-amino esters) deliver mRNA to lung cells via nebulization, reducing toxicity while maintaining transfection efficiency.

Ergothioneine antioxidant compound inhibits the TLR-4/MyD88/NF-kB signaling pathway to reduce oxidative stress and inflammatory factor release.

Selective AT2 receptor antagonism reduces neuropathic pain and side effects while restoring nerve conduction velocity.

Piperidinyl-propanone derivatives selectively target PDHK2 to reduce cancer cell burden while preserving normal cellular function and patient viability.

Reversible hetero-bicyclic compounds minimize hepatotoxicity and off-target effects while maintaining therapeutic efficacy.

Synergistic capsaicin and astaxanthin composition targets inflammaging by down-regulating NF-kβ activation and reducing oxidative stress.

Alanyl-glutamine formulations stimulate natural cell proliferation to accelerate wound closure while reducing inflammation and scarring risks.

CYP11A1 inhibitors suppress intratumoral steroid synthesis by blocking cholesterol conversion, overcoming resistance in castration-resistant prostate cancer.

Formula E and V compounds modulate liver X receptor activity to stimulate epidermal differentiation and lipid production.

Humanizing murine anti-VISTA antibodies reduces immunogenicity while maintaining binding strength and tumor growth inhibition.

Specific compounds modulate ATF6 signaling to overcome treatment resistance in cancer and neurodegenerative disorders.

Adamantyl retinoid derivatives overcome tumor cell resistance by bypassing epigenetic silencing of the RAR-beta receptor.

Marine lecithin treats psoriasis without corticosteroid side effects or UV cancer risk.

An epoxide-based crosslinking agent creates a composite structure that reduces stickiness while maintaining high concentration moisturizing effects.

Alkaline earth metal salts enable direct cyclization of chloroethyl precursors to form condensed imidazolo derivatives without auxiliary ester groups.

IL-1R antagonists block sterile inflammation while preserving host defense and tissue repair functions.

Dimyricetin-yl-diselenide reduces aortic plaque area and blood lipid levels to address high mortality rates in coronary heart disease patients.

Introducing desaturase and elongase sequences into transgenic plants to boost polyunsaturated fatty acid yields.

A translation-based gene regulation system controls protein expression through nonsense mutations in mammalian cells.

IMPDH inhibitors deplete purine pools in glioblastoma cells, overcoming chemoresistance and increasing DNA damage from Temozolomide treatment.

Replacing ethanol with dichloromethane suppresses 3-O-sulfonylated impurities and simplifies filtration.

Modified propolin G derivatives resolve efficacy versus specificity trade-offs in HDAC inhibition, treating neurodegenerative diseases.

Phenylpropionamide compounds target peripheral opioid receptors to provide analgesia.

Combines a TLR8 modulator with anti-HBV siRNA to activate latent infected cells.

Stable meloxicam injectable solution uses meglumine and cyclodextrin derivatives to enhance solubility for parenteral administration.

Meta tyrosine derivatives inhibit ROCK enzymes through meta-position substitutions, enabling selective isoform targeting for pulmonary disease treatment.

Novel azetidine-substituted dihydrothienopyrimidines inhibit phosphodiesterase 4 with enhanced metabolic stability.

Nitrogen-containing polycyclic fused ring compound inhibits RET kinase activity, resolving off-target toxicity and resistance in thyroid cancer treatment.

Crystallizing crude (S)-oxiracetam with acetone and water yields crystal form I, achieving purity exceeding 99.3% to treat memory dysfunction.

Specific pyridine and triazine derivatives block triglyceride synthesis via enzyme inhibition, addressing limitations of existing therapies.

Merges bupropion and trazodone to address limited efficacy of monotherapy, providing synergistic treatment for hypoactive sexual desire disorder.

Liposomal microparticles encapsulate TPA-crosslinked and TPP-crosslinked chitosan nanoparticles to deliver actinomycin D and telmisartan.

Hyaluronic acid conjugates with EGCG via horseradish peroxidase enable targeted anti-cancer effects while minimizing pro-oxidant activity.

Developing stable polymorphs of Compound A mesylate addresses cancer cell heterogeneity and unpredictable chemotherapeutic responses.

Combining pemigatinib with enfortumab vedotin targets FGFR activity and Nectin-4 for synergistic cancer treatment.

Merges an endothelin receptor antagonist with a prostacyclin agonist to resolve the contradiction between therapeutic efficacy and side effects like flushing.

Formula I compounds inhibit RET kinase activity through selective binding, reducing off-target toxicities while targeting resistant mutants.

Extended nanoparticle infusion reduces toxicological side effects while maintaining therapeutic efficacy.

Ionizable lipid nanoparticles protect siRNA from renal clearance and enzymatic degradation while enabling efficient cellular uptake.

A transdermal preparation uses a drug permeable polymer membrane to control active agent release from the laminate structure.

L552 peptide directs COMMD1 protein to cancer cell nuclei, inhibiting proliferation and reducing chemotherapy toxicity.

3-OH-kynurenamine downregulates the NF-κB pathway, reducing inflammatory manifestations and promoting immune tolerance.

Formula I compounds inhibit SHP2 enzymatic activity, addressing the lack of effective small molecule therapies for cancers and hematological disorders.

Direct mTOR kinase domain inhibition by morpholino pyrimidines resolves variable Rapamycin efficacy through parameter changes.

Modified RNA encoding VEGF-A proteins formulated in citrate saline buffer eliminates cationic lipid toxicity while sustaining vascular function.

Administering mTOR inhibitors to halt malignant conversion of precancerous lesions in at-risk individuals.

FJU-C28 suppresses inflammatory mediators to reduce lung damage, addressing high mortality from acute respiratory distress syndrome.

A gamma-quaternary ammonium butyrate compound increases average daily weight gain in livestock without altering feed intake levels.

C21-substituted neuroactive steroids modulate GABA receptors, establishing clear dose-response relationships for treating CNS disorders.

A personal care composition combines a strobilurin and a 2-pyridinol-N-oxide material to deliver synergistic anti-inflammatory activity.

An expandable member transfers drug crystals to target tissue, forming a sustained-release depot that maintains therapeutic levels and reduces dosing frequency.

A quinazolinone derivative inhibits angiogenic factors and cytokine production to manage refractory cancers.

Targeting cancer stem cells with let-7 microRNA reduces self-renewal and prevents tumor recurrence despite low cell frequency.

4-substituted bicyclo[3.1.0]hexane compounds enhance bioavailability to treat psychiatric disorders.